Complementary Therapies Availability Poses Threat To Controlled Liver Trials
This article was originally published in The Tan Sheet
Executive Summary
Widespread use of alternative medicines for chronic liver disease will complicate randomized, controlled trials of those substances, former NIH Office of Alternative Medicine Director Wayne Jonas, MD, told a National Institutes of Health workshop on "Complementary and Alternative Medicine in Chronic Liver Disease" Aug. 23.